Omkar Pharmachem Ltd has scheduled its 31st Annual General Meeting (AGM) for Wednesday, September 30, 2026. The meeting will be held at Hotel Kanak in Ahmedabad to transact ordinary and special business, including the re-appointment of a retiring director and the approval of material related-party transactions.

The company submitted the notice of the AGM to the Bombay Stock Exchange on September 2, 2026. The Board of Directors approved the notice and other corporate actions during a meeting held on August 31, 2026.

Key Agenda Items

The AGM will address three primary items of business:

1. Adoption of Financial Statements: Shareholders will receive, consider, and adopt the audited financial statements for the financial year ended March 31, 2026, along with the reports of the directors and auditors.
2. Director Re-appointment: The board proposes the re-appointment of Mr. Parminder Sharma (DIN: 00176300), who retires by rotation at this AGM and has offered himself for re-election.
3. Material Related-Party Transactions (RPTs): The company seeks shareholder approval for recurring transactions with Key Managerial Personnel (KMPs), specifically the Company Secretary and Chief Financial Officer.

Related-Party Transaction Details

The proposed RPTs involve the payment of remuneration to Mr. Pankaj Singh (Company Secretary) and Mr. Arun Kumar (Chief Financial Officer). These transactions are classified as material because their aggregate value is expected to exceed 10% of the company’s annual consolidated turnover as per the last audited financial statements.

The board confirmed that these transactions are conducted at arm's length and in the ordinary course of business. Prior approval from the Audit Committee has been obtained.

E-Voting and Logistics

Shareholders holding shares on the record date of September 23, 2026, are eligible to vote. Remote e-voting will be facilitated by Central Depository Services (India) Limited (CDSL).

• Voting Period: Begins Sunday, September 27, 2026, at 9:00 am and ends Tuesday, September 29, 2026, at 5:00 pm.
• Scrutinizer: M/s Maulik Bhavsar & Associates has been appointed to scrutinize the voting process.
• Meeting Venue: Hotel Kanak, Opp-Gujarat College, Ellisbridge, Ahmedabad-380006.

Members attending the meeting who have not cast their votes via remote e-voting may exercise their right to vote through ballot papers at the venue.

Omkar Pharmachem reported a net loss of ₹1.00 lakh for the quarter ended June 30, 2026, marking a shift from the ₹1.50 lakh profit recorded in the immediately preceding quarter ended March 31, 2026. The Board of Directors approved the unaudited standalone financial results on August 13, 2026. The results were reviewed by the audit committee and in accordance with Standard on Review Engagement (SRE) 2410 by Dipal R. Shah & Co., Chartered Accountants.

The company generated zero income from core operations, with net sales remaining at nil. Total income from operations was confined to ₹9.00 lakh from other operating income, which remained stable compared to the prior quarter but fell from ₹13.50 lakh in the same period last year. Other income was nil for the current quarter, compared to ₹0.30 lakh in the previous quarter.

Financial Performance

Total expenses increased to ₹10.00 lakh from ₹7.35 lakh in the previous quarter. This rise was largely attributable to an increase in other expenses, which jumped to ₹4.82 lakh from ₹2.13 lakh. Employee benefits remained steady at ₹5.14 lakh, while depreciation and amortization costs decreased slightly to ₹0.04 lakh from ₹0.08 lakh. There were no exceptional items or tax expenses reported for the quarter.

What the Numbers Show

The financial data reveals a complete absence of operational revenue generation during the quarter. With net sales at zero, the company’s ability to cover fixed costs relied entirely on non-operating income streams. The widening loss despite stable other operating income highlights the pressure from variable other expenses, which more than doubled compared to the previous quarter, eroding the thin margin previously supported by lower cost structures.